Clinical Trial Update: Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02) [Phase 1]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 1 study (E2609-A001-101 Amendment 02) evaluating the drug E2609 in subjects with mild cognitive imp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• E2609

Snippet

Sponsor: Eisai Inc. | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED